• Investing
  • Stock
  • Editor’s Pick
  • Economy
The Significant Deals
Stock

General Motors stock rises as Q3 earnings surpass expectations

by October 22, 2024
written by October 22, 2024

Investing.com — General Motors Co. reported third-quarter earnings that exceeded analyst estimates, driving its stock up 3% in early trading. The automaker’s strong performance was fueled by robust revenue growth and improved profitability.

GM posted adjusted earnings per share of $2.96, surpassing the analyst consensus of $2.40 by $0.56. Revenue for the quarter reached $48.76 billion, significantly beating the expected $44.74 billion and marking a 10.5% increase YoY.

The company’s EBIT-adjusted rose 15.5% YoY to $4.1 billion, with an EBIT-adjusted margin of 8.4%, up 0.3 percentage points from the same period last year. GM’s North American operations continued to be a key driver, with EBIT-adjusted of $3.98 billion, up 12.9% YoY.

“GM is delivering our best vehicles ever with strong financial results,” said CEO Mary Barra. “But I want to be clear that we are not mistaking progress for winning. Competition is fierce, and the regulatory environment will keep getting tougher.”

In light of its strong performance, GM raised its full-year 2024 guidance. The company now expects EBIT-adjusted between $14 billion and $15 billion, up from the previous range of $13 billion to $15 billion. GM also increased its adjusted EPS forecast to $10.00-$10.50, above the analyst consensus of $9.97.

The automaker’s improved outlook reflects its progress in EV profitability, rising sales, and market share growth. GM also cited improved performance in China, despite reporting an equity loss of $137 million in the region for the quarter.

GM’s financial guidance includes anticipated capital spending of $10.5 billion to $11.5 billion for 2024, which encompasses investments in battery cell manufacturing joint ventures.

This post appeared first on investing.com
0 comment
0
FacebookTwitterPinterestEmail

previous post
3M raises lower end of full-year adjusted profit forecast on demand recovery
next post
Eurofins Scientific says financial audit refutes short seller allegations

You may also like

BASF results down on impairments, restructuring

January 27, 2025

European chipmakers slump as traders gauge DeepSeek AI...

January 27, 2025

Nasdaq futures tumble as China’s AI push rattles...

January 27, 2025

China Vanke’s CEO, chairman resign amid growing liquidity...

January 27, 2025

Fuji Media, rocked by sexual misconduct allegations, says...

January 27, 2025

Italy’s MPS shares fall ahead of Mediobanca board...

January 27, 2025

British Land stock drops following stake sale

January 27, 2025

UMG shares rally after new multi-year pact with...

January 27, 2025

BASF shares indicated 3% lower as impairments drag...

January 27, 2025

Ryanair cuts 2026 traffic forecast amid ongoing Boeing...

January 27, 2025
Fill Out & Get More Relevant News








    Stay ahead of the market and unlock exclusive trading insights & timely news. We value your privacy - your information is secure, and you can unsubscribe anytime. Gain an edge with hand-picked trading opportunities, stay informed with market-moving updates, and learn from expert tips & strategies.

    Recent Posts

    • Divided Fed proposes rule to ease capital requirements for big Wall Street banks

      June 26, 2025
    • Women’s Tennis Association extends media rights deal with Tennis Channel through 2032

      June 26, 2025
    • Bumble shares jump 26% as dating company plans to axe 30% of workforce

      June 26, 2025
    • Small-business AI use is lagging, but one firm is channeling Sherlock Holmes and knocking out ‘grunt work’

      June 25, 2025

    Categories

    • Economy (245)
    • Editor's Pick (3,646)
    • Investing (534)
    • Stock (6,426)

    Latest News

    • Divided Fed proposes rule to ease capital requirements for big Wall Street banks
    • Women’s Tennis Association extends media rights deal with Tennis Channel through 2032

    Popular News

    • Dick’s Sporting Goods stands by full-year guidance — even with tariffs looming
    • Pfizer to sell $3 billion stake in Sensodyne maker Haleon

    About The Significant deals

    • Privacy Policy
    • Terms & Conditions

    Copyright © 2025 thesignificantdeals.com | All Rights Reserved

    The Significant Deals
    • Investing
    • Stock
    • Editor’s Pick
    • Economy